Discoidin domain receptors: A proteomic portrait

Cellular and Molecular Life Sciences

Volumn 71, Issue 17, 2014, Pages 3269-3279

  Iwai, Leo K ^a,b   Luczynski, Maciej T ^a   Huang, Paul H ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

Cell signaling; Collagen; Discoidin domain receptors; Mass spectrometry; Proteomics

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ALVESPIMYCIN; BCR ABL PROTEIN; COLLAGEN BINDING PROTEIN; DASATINIB; DISCOIDIN; DISCOIDIN DOMAIN RECEPTOR; DISCOIDIN DOMAIN RECEPTOR 1; DISCOIDIN DOMAIN RECEPTOR 2; FORETINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMATINIB; NILOTINIB; PERVANADATE; PHOSPHOPROTEIN; PROTEIN TYROSINE KINASE; SELUMETINIB; SORAFENIB; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER CELL LINE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CERVICAL CANCER CELL LINE; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DNA METABOLISM; DRUG MECHANISM; DRUG RECEPTOR BINDING; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; LOW DRUG DOSE; LUNG CANCER CELL LINE; MASS SPECTROMETRY; MULTIPLE CANCER; NEOPLASM; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PHYSIOLOGICAL PROCESSES; ENZYME ACTIVATION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MESODERM; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHORYLATION; PROTEIN INTERACTION MAPPING; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, MITOGEN; SIGNAL TRANSDUCTION;

EID: 84906255509     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-014-1616-1     Document Type: Review

References (91)

1. Fu HL et al (2013) Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J Biol Chem 288(11):7430-7437
2. Leitinger B (2011) Transmembrane collagen receptors. Annu Rev Cell Dev Biol 27:265-290
3. Valiathan RR et al (2012) Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev 31(1-2):295-321
4. Vogel WF, Abdulhussein R, Ford CE (2006) Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal 18(8):1108-1116 (Pubitemid 43674043)
5. Maeyama M et al (2008) Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. Cancer 113(10):2823-2831
6. Walsh LA, Nawshad A, Medici D (2011) Discoidin domain receptor 2 is a critical regulator of epithelial-mesenchymal transition. Matrix Biol 30(4):243-247
7. Carafoli F, Hohenester E (2013) Collagen recognition and transmembrane signalling by discoidin domain receptors. Biochim Biophys Acta 1834(10):2187-2194
8. Leitinger B, Hohenester E (2007) Mammalian collagen receptors. Matrix Biol 26(3):146-155 (Pubitemid 46401227)
9. Leitinger B, Kwan AP (2006) The discoidin domain receptor DDR2 is a receptor for type X collagen. Matrix Biol 25(6):355-364 (Pubitemid 44175833)
10. Shrivastava A et al (1997) An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell 1(1):25-34 (Pubitemid 127376390)
11. Vogel W et al (1997) The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1(1):13-23 (Pubitemid 127376389)
12. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411(6835):355-365 (Pubitemid 32467045)
13. Cohen P, Alessi DR (2013) Kinase drug discovery - what's next in the field? ACS Chem Biol 8(1):96-104
14. Lynch TJ et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139 (Pubitemid 38637993)
15. Gerber DE, Minna JD (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18(6):548-551
16. Druker BJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031-1037 (Pubitemid 32267972)
17. Weiner HL et al (2000) Consistent and selective expression of the discoidin domain receptor-1 tyrosine kinase in human brain tumors. Neurosurgery 47(6):1400-1409
18. Yamanaka R et al (2006) Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 25(44):5994-6002 (Pubitemid 44477293)
19. Hammerman PS et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1(1):78-89
20. Ren T et al (2013) Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients. Med Oncol 30(1):397
21. Ford CE et al (2007) Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer 96(5):808-814 (Pubitemid 46380188)
22. Van Schaeybroeck S et al (2005) Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 11(20):7480-7489 (Pubitemid 41507709)
23. Thomson S et al (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65(20):9455-9462 (Pubitemid 41508014)
24. Rikova K et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6):1190-1203 (Pubitemid 350235027)
25. Amann J et al (2005) Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65(1):226-235 (Pubitemid 40070814)
26. Garofalo M et al (2012) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18(1):74-82
27. Ishikawa M et al (2012) Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer 76(3):431-438
28. van Kempen LC et al (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82(11):539-548 (Pubitemid 38008835)
29. Gu TL et al (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6(1):e15640
30. Bai Y et al (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72(10):2501-2511
31. Alitalo K et al (1982) Biosynthesis of type V procollagen by A204, a human rhabdomyosarcoma cell line. J Biol Chem 257(15):9016-9024 (Pubitemid 12001869)
32. Kleman JP et al (1992) The human rhabdomyosarcoma cell line A204 lays down a highly insoluble matrix composed mainly of alpha 1 type-XI and alpha 2 type-V collagen chains. Eur J Biochem 210(1):329-335
33. Xu AM, Huang PH (2010) Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 70(10):3857-3860
34. Huang PH (2012) Phosphoproteomic studies of receptor tyrosine kinases: future perspectives. Mol BioSyst 8(4):1100-1107
35. Johnson H et al (2012) Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. Mol Cell Proteomics 11(12):1724-1740
36. Iwai LK, Chang F, Huang PH (2013) Phosphoproteomic analysis identifies insulin enhancement of discoidin domain receptor 2 phosphorylation. Cell Adh Migr 7(2):161-164
37. Meyer AS et al (2013) The Receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal 6(287):ra66
38. Vajpai N et al (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 283(26):18292-18302
39. Bantscheff M et al (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotech 25(9):1035-1044 (Pubitemid 47517638)
40. Weisberg E et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2):129-141 (Pubitemid 40248339)
41. Rix U et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110(12):4055-4063 (Pubitemid 350248462)
42. Joensuu H et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052-1056 (Pubitemid 32267975)
43. Demetri GD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472-480 (Pubitemid 34879334)
44. Heinrich MC et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342-4349 (Pubitemid 46621810)
45. Day E et al (2008) Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 599(1-3):44-53
46. Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11(7):515-528
47. Sharma K et al (2012) Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response. Mol Cell Proteomics 11(3):M111.014654. doi:10.1074/mcp.M111.014654
48. Wu Z, Moghaddas Gholami A, Kuster B (2012) Systematic identification of the HSP90 candidate regulated proteome. Mol Cell Proteomics 11(6):M111.016675. doi:10.1074/mcp.M111.016675
49. Haupt A et al (2012) Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics. BMC Cancer 12:38
50. Li J et al (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6(4):291-299
51. Gorre ME et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876-880 (Pubitemid 32743979)
52. Pao W et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73
53. Beauchamp EM et al (2013) Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther 13(2):475-482
54. Polier S et al (2013) ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol 9(5):307-312
55. Siddiqui K et al (2009) Actinomycin D identified as an inhibitor of discoidin domain receptor 2 interaction with collagen through an insect cell-based screening of a drug compound library. Biol Pharm Bull 32(1):136-141
56. Hu Y et al (2013) Discoipyrroles A-D: isolation, structure determination, and synthesis of potent migration inhibitors from Bacillus hunanensis. J Am Chem Soc 135(36):13387-13392
57. Potts MB et al (2013) Using functional signature ontology (FUSION) to identify mechanisms of action for natural products. Sci Signal 6(297):ra90
58. Gao M et al (2013) Discovery and optimization of 3-(2-(Pyrazolo[1,5-a] pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. J Med Chem 56(8):3281-3295
59. Kim HG et al (2013) Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol 8(10):2145-2150
60. Duncan JS et al (2012) Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149(2):307-321
61. Dang CV (2012) MYC on the path to cancer. Cell 149(1):22-35
62. L'Hote CG, Thomas PH, Ganesan TS (2002) Functional analysis of discoidin domain receptor 1: effect of adhesion on DDR1 phosphorylation. FASEB J 16(2):234-236
63. Koo DH et al (2006) Pinpointing phosphotyrosine-dependent interactions downstream of the collagen receptor DDR1. FEBS Lett 580(1):15-22 (Pubitemid 43005305)
64. Wang CZ et al (2006) A discoidin domain receptor 1/SHP-2 signaling complex inhibits alpha2beta1-integrin-mediated signal transducers and activators of transcription 1/3 activation and cell migration. Mol Biol Cell 17(6):2839-2852
65. Yang G et al (2009) Proteomic, functional and motif-based analysis of C-terminal Src kinase-interacting proteins. Proteomics 9(21):4944-4961
66. Lin KL et al (2010) Transcriptional upregulation of DDR2 by ATF4 facilitates osteoblastic differentiation through p38 MAPK-mediated Runx2 activation. J Bone Miner Res 25(11):2489-2503
67. Zhang Y et al (2011) An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation. J Bone Miner Res 26(3):604-617
68. Lemeer S et al (2012) Phosphotyrosine-mediated protein interactions of the discoidin domain receptor 1. J Proteomics 75(12):3465-3477
69. Faraci-Orf E, McFadden C, Vogel WF (2006) DDR1 signaling is essential to sustain Stat5 function during lactogenesis. J Cell Biochem 97(1):109-121 (Pubitemid 43050183)
70. Kim HG et al (2011) DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation. J Biol Chem 286(20):17672-17681
71. Dejmek J et al (2005) Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res 11(2 Pt 1):520-528 (Pubitemid 40116875)
72. Huang Y et al (2009) The collagen receptor DDR1 regulates cell spreading and motility by associating with myosin IIA. J Cell Sci 122(Pt 10):1637-1646
73. Shintani Y et al (2008) Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J Cell Biol 180(6):1277-1289 (Pubitemid 351468480)
74. Hidalgo-Carcedo C et al (2011) Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. Nat Cell Biol 13(1):49-58
75. Hansen C et al (2006) Phosphorylation of DARPP-32 regulates breast cancer cell migration downstream of the receptor tyrosine kinase DDR1. Exp Cell Res 312(20):4011-4018 (Pubitemid 44828046)
76. Hilton HN et al (2008) KIBRA interacts with discoidin domain receptor 1 to modulate collagen-induced signalling. Biochim Biophys Acta 1783(3):383-393
77. Das S et al (2006) Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-kappaB pathway activation. Cancer Res 66(16):8123-8130 (Pubitemid 44299179)
78. Iwai LK et al (2013) Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Biochem J 454(3):501-513
79. Furdui CM et al (2006) Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell 21(5):711-717 (Pubitemid 43290737)
80. Yang K et al (2005) Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation. J Biol Chem 280(47):39058-39066 (Pubitemid 41713856)
81. Ikeda K et al (2002) Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem 277(21):19206-19212 (Pubitemid 34952488)
82. Su J et al (2009) Discoidin domain receptor 2 is associated with the increased expression of matrix metalloproteinase-13 in synovial fibroblasts of rheumatoid arthritis. Mol Cell Biochem 330(1-2):141-152
83. Noordeen NA et al (2006) A transmembrane leucine zipper is required for activation of the dimeric receptor tyrosine kinase DDR1. J Biol Chem 281(32):22744-22751
84. Mihai C et al (2009) Mapping of DDR1 distribution and oligomerization on the cell surface by FRET microscopy. J Mol Biol 385(2):432-445
85. Fu, HL et al (2014) Glycosylation at ASN211 regulates the activation state of the discoidin domain receptor 1 (DDR1). J Biol Chem
86. Lew ED et al (2009) The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal 2(58):ra6
87. Payne LS, Huang PH (2013) The pathobiology of collagens in glioma. Mol Cancer Res 11(10):1129-1140
88. Fu HL et al (2013) Shedding of discoidin domain receptor 1 by membrane-type matrix metalloproteinases. J Biol Chem 288(17):12114-12129
89. Carafoli F et al (2009) Crystallographic insight into collagen recognition by discoidin domain receptor 2. Structure 17(12):1573-1581
90. Xu H et al (2012) Discoidin domain receptors promote alpha-1beta1- and alpha2beta1-integrin-mediated cell adhesion to collagen by enhancing integrin activation. PLoS One 7(12):e52209
91. Zheng Y et al (2013) Temporal regulation of EGF signalling networks by the scaffold protein Shc1. Nature 499(7457):166-171